BioXcel Therapeutics entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026. The amendment extends the deadline for completing a transaction resulting in full loan repayment or alternative capital solutions to August 21, 2026. Additionally, lenders reduced the minimum liquidity covenant requirement from $6.25 million to $3.0 million. BioXcel Therapeutics operates in the biotechnology industry, focusing on the development of pharmaceutical treatments for central nervous system disorders.
